AMSilk X Balenciaga: Fashion Success for an Understated Executor
The biomaterials sector is bifurcating. While Bolt Threads delists and Spiber restructures, AMSilk has quietly arrived in Balenciaga's Spring 2026 collection with two products on sale now. Through an interview with AMSilk's Head of Marketing, I examine what the Understated Executor archetype looks like when it reaches commercial luxury, and why even this success story surfaces a deeper structural question the category has yet to answer.
The $300M Wake-Up Call (part 2): Measuring the Gap°
Three of biomaterials' highest-funded companies ceased operations between 2023-2025. Using a 61-company dataset, I developed the Commercial Readiness Compass to measure the Gap° between what companies claim and what they can prove. Five archetypes emerged, revealing how companies that maintain alignment between story and proof retain credibility, while those whose visibility outpaces verification experience existential collapse.
The $300M Wake-Up Call: Why BioMaterials Need a New Branding Playbook
“However, as new material innovations increasingly focus on invisible virtue (sustainability) or parity (mimicking heritage products) rather than purely disruptive function, the foundational rules that guided Gore-Tex's rise may now prove incomplete for navigating the modern market…"